Skip to main content
All lobbying filings

TEVA PHARMACEUTICALS USA, INC.

Lobbying for TEVA PHARMACEUTICALS USA INC

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 18, 2025
Expenses
$310,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
New Jersey

Official filing document

 Government bodies contacted 9
  • Centers For Medicare and Medicaid Services (CMS)
  • Commerce, Dept of (DOC)
  • Executive Office of the President (EOP)
  • Food & Drug Administration (FDA)
  • Health & Human Services, Dept of (HHS)
  • Homeland Security, Dept of (DHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE
  • U.S. Trade Representative (USTR)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 1
  • SJRES 37
    A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada.
 Lobbying activity 2
Health Issues

Use of Section viii statements in pharmaceutical labeling. FDAs approval of over-the-counter naloxone nasal spray. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and legislation to reform pharmacy benefit managers. Patent reform legislation. Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA).

Tariff (miscellaneous tariff bills)

A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37).

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem